Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
Inflammation influences cancer development and progression. An elevated platelet to lymphocyte ratio (PLR), a marker of inflammation, has been linked to poor prognosis in several malignancies. Here, we quantify the prognostic impact of this biomarker. A systematic review of databases was conducted t...
Gespeichert in:
Veröffentlicht in: | Cancer epidemiology, biomarkers & prevention biomarkers & prevention, 2014-07, Vol.23 (7), p.1204-1212 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1212 |
---|---|
container_issue | 7 |
container_start_page | 1204 |
container_title | Cancer epidemiology, biomarkers & prevention |
container_volume | 23 |
creator | TEMPLETON, Arnoud J ACE, Olga MCNAMARA, Mairéad G AL-MUBARAK, Mustafa VERA-BADILLO, Francisco E HERMANNS, Thomas SERUGA, Boštjan OCANA, Alberto TANNOCK, Ian F AMIR, Eitan |
description | Inflammation influences cancer development and progression. An elevated platelet to lymphocyte ratio (PLR), a marker of inflammation, has been linked to poor prognosis in several malignancies. Here, we quantify the prognostic impact of this biomarker.
A systematic review of databases was conducted to identify publications exploring the association of blood PLR and overall survival (OS) in solid tumors. Data were pooled in a meta-analysis. Pooled HRs for OS by disease group and by PLR cutoff groups were computed and weighted using generic inverse-variance and random-effect modeling.
Twenty studies comprising 12,754 patients were assessed. Cutoffs for PLR defining risk groups ranged from 150 to 300 and were dichotomous (12 studies; group 1) or split into three groups (300, 8 studies; group 2). Higher PLR was associated with significantly worse OS in group 1 [HR = 1.87; 95% confidence interval (CI, 1.49-2.34); P < 0.001] and with a nonsignificant association in group 2 (HR per higher category = 1.21; 95%CI, 0.97-1.50; P = 0.10). The size of effect of PLR on OS was greater for metastatic disease (HR[group 1] = 2.0; 95% CI, 1.6-2.7; HR[group 2] = 1.6; 95% CI, 1.1-2.4) than for early-stage disease (HR[group 1] = 1.5; 95% CI, 1.0-2.2; HR[group 2] = 1.0; 95% CI, 0.8-1.3). A significant association was observed for colorectal, hepatocellular, gastroesophageal, ovarian, and pancreatic carcinoma in group 1 and for colorectal cancers in group 2.
A high PLR is associated with worse OS in various solid tumors. Further research of its regulation and relevance in daily practice is warranted.
PLR is a readily available and inexpensive biomarker with independent prognostic value in solid tumors. |
doi_str_mv | 10.1158/1055-9965.epi-14-0146 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1543279151</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1543279151</sourcerecordid><originalsourceid>FETCH-LOGICAL-c556t-b2f87612ba5d8cef018473f01866e52dfb8be54ab981fdad3d63503e0644cc813</originalsourceid><addsrcrecordid>eNpFkE1P3DAQhq2qVflof0KRL5W4BOzYkzi9rRBf0qKugJ4txxm3Rk68jb2g_Hs2sMBp5vC872geQn5wdsI5qFPOAIqmqeAE177gsmBcVp_IPgehiroG-Lzd35g9cpDSA2OsbgC-kr1S1o1oQO0Ttxrj3yGm7C29jQFpdHQVTMaAmeZIl1O__hftlJHemuwj9QO9i8F39H7TxzH9ogt6N6WMvXmpwEePT9QMHb3BbIrFYMKUfPpGvjgTEn7fzUPy5-L8_uyqWP6-vD5bLAsLUOWiLZ2qK162Bjpl0TGuZC3mUVUIZeda1SJI0zaKu850oqsEMIGsktJaxcUhOX7tXY_x_wZT1r1PFkMwA8ZN0hykKOuGw4zCK2rHmNKITq9H35tx0pzpWbGe9elZnz5fXWsu9ax4mzvandi0PXbvqTenW-DnDjDJmuBGM1ifPrjtL6JmUjwDyyOE7w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1543279151</pqid></control><display><type>article</type><title>Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>TEMPLETON, Arnoud J ; ACE, Olga ; MCNAMARA, Mairéad G ; AL-MUBARAK, Mustafa ; VERA-BADILLO, Francisco E ; HERMANNS, Thomas ; SERUGA, Boštjan ; OCANA, Alberto ; TANNOCK, Ian F ; AMIR, Eitan</creator><creatorcontrib>TEMPLETON, Arnoud J ; ACE, Olga ; MCNAMARA, Mairéad G ; AL-MUBARAK, Mustafa ; VERA-BADILLO, Francisco E ; HERMANNS, Thomas ; SERUGA, Boštjan ; OCANA, Alberto ; TANNOCK, Ian F ; AMIR, Eitan</creatorcontrib><description>Inflammation influences cancer development and progression. An elevated platelet to lymphocyte ratio (PLR), a marker of inflammation, has been linked to poor prognosis in several malignancies. Here, we quantify the prognostic impact of this biomarker.
A systematic review of databases was conducted to identify publications exploring the association of blood PLR and overall survival (OS) in solid tumors. Data were pooled in a meta-analysis. Pooled HRs for OS by disease group and by PLR cutoff groups were computed and weighted using generic inverse-variance and random-effect modeling.
Twenty studies comprising 12,754 patients were assessed. Cutoffs for PLR defining risk groups ranged from 150 to 300 and were dichotomous (12 studies; group 1) or split into three groups (<150/150-300/>300, 8 studies; group 2). Higher PLR was associated with significantly worse OS in group 1 [HR = 1.87; 95% confidence interval (CI, 1.49-2.34); P < 0.001] and with a nonsignificant association in group 2 (HR per higher category = 1.21; 95%CI, 0.97-1.50; P = 0.10). The size of effect of PLR on OS was greater for metastatic disease (HR[group 1] = 2.0; 95% CI, 1.6-2.7; HR[group 2] = 1.6; 95% CI, 1.1-2.4) than for early-stage disease (HR[group 1] = 1.5; 95% CI, 1.0-2.2; HR[group 2] = 1.0; 95% CI, 0.8-1.3). A significant association was observed for colorectal, hepatocellular, gastroesophageal, ovarian, and pancreatic carcinoma in group 1 and for colorectal cancers in group 2.
A high PLR is associated with worse OS in various solid tumors. Further research of its regulation and relevance in daily practice is warranted.
PLR is a readily available and inexpensive biomarker with independent prognostic value in solid tumors.</description><identifier>ISSN: 1055-9965</identifier><identifier>EISSN: 1538-7755</identifier><identifier>DOI: 10.1158/1055-9965.epi-14-0146</identifier><identifier>PMID: 24793958</identifier><identifier>CODEN: CEBPE4</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Biological and medical sciences ; Humans ; Lymphocyte Count ; Medical sciences ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Neoplasms - blood ; Neoplasms - mortality ; Platelet Count ; Prognosis ; Tumors</subject><ispartof>Cancer epidemiology, biomarkers & prevention, 2014-07, Vol.23 (7), p.1204-1212</ispartof><rights>2015 INIST-CNRS</rights><rights>2014 American Association for Cancer Research.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c556t-b2f87612ba5d8cef018473f01866e52dfb8be54ab981fdad3d63503e0644cc813</citedby><cites>FETCH-LOGICAL-c556t-b2f87612ba5d8cef018473f01866e52dfb8be54ab981fdad3d63503e0644cc813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28663704$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24793958$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>TEMPLETON, Arnoud J</creatorcontrib><creatorcontrib>ACE, Olga</creatorcontrib><creatorcontrib>MCNAMARA, Mairéad G</creatorcontrib><creatorcontrib>AL-MUBARAK, Mustafa</creatorcontrib><creatorcontrib>VERA-BADILLO, Francisco E</creatorcontrib><creatorcontrib>HERMANNS, Thomas</creatorcontrib><creatorcontrib>SERUGA, Boštjan</creatorcontrib><creatorcontrib>OCANA, Alberto</creatorcontrib><creatorcontrib>TANNOCK, Ian F</creatorcontrib><creatorcontrib>AMIR, Eitan</creatorcontrib><title>Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis</title><title>Cancer epidemiology, biomarkers & prevention</title><addtitle>Cancer Epidemiol Biomarkers Prev</addtitle><description>Inflammation influences cancer development and progression. An elevated platelet to lymphocyte ratio (PLR), a marker of inflammation, has been linked to poor prognosis in several malignancies. Here, we quantify the prognostic impact of this biomarker.
A systematic review of databases was conducted to identify publications exploring the association of blood PLR and overall survival (OS) in solid tumors. Data were pooled in a meta-analysis. Pooled HRs for OS by disease group and by PLR cutoff groups were computed and weighted using generic inverse-variance and random-effect modeling.
Twenty studies comprising 12,754 patients were assessed. Cutoffs for PLR defining risk groups ranged from 150 to 300 and were dichotomous (12 studies; group 1) or split into three groups (<150/150-300/>300, 8 studies; group 2). Higher PLR was associated with significantly worse OS in group 1 [HR = 1.87; 95% confidence interval (CI, 1.49-2.34); P < 0.001] and with a nonsignificant association in group 2 (HR per higher category = 1.21; 95%CI, 0.97-1.50; P = 0.10). The size of effect of PLR on OS was greater for metastatic disease (HR[group 1] = 2.0; 95% CI, 1.6-2.7; HR[group 2] = 1.6; 95% CI, 1.1-2.4) than for early-stage disease (HR[group 1] = 1.5; 95% CI, 1.0-2.2; HR[group 2] = 1.0; 95% CI, 0.8-1.3). A significant association was observed for colorectal, hepatocellular, gastroesophageal, ovarian, and pancreatic carcinoma in group 1 and for colorectal cancers in group 2.
A high PLR is associated with worse OS in various solid tumors. Further research of its regulation and relevance in daily practice is warranted.
PLR is a readily available and inexpensive biomarker with independent prognostic value in solid tumors.</description><subject>Biological and medical sciences</subject><subject>Humans</subject><subject>Lymphocyte Count</subject><subject>Medical sciences</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Neoplasms - blood</subject><subject>Neoplasms - mortality</subject><subject>Platelet Count</subject><subject>Prognosis</subject><subject>Tumors</subject><issn>1055-9965</issn><issn>1538-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1P3DAQhq2qVflof0KRL5W4BOzYkzi9rRBf0qKugJ4txxm3Rk68jb2g_Hs2sMBp5vC872geQn5wdsI5qFPOAIqmqeAE177gsmBcVp_IPgehiroG-Lzd35g9cpDSA2OsbgC-kr1S1o1oQO0Ttxrj3yGm7C29jQFpdHQVTMaAmeZIl1O__hftlJHemuwj9QO9i8F39H7TxzH9ogt6N6WMvXmpwEePT9QMHb3BbIrFYMKUfPpGvjgTEn7fzUPy5-L8_uyqWP6-vD5bLAsLUOWiLZ2qK162Bjpl0TGuZC3mUVUIZeda1SJI0zaKu850oqsEMIGsktJaxcUhOX7tXY_x_wZT1r1PFkMwA8ZN0hykKOuGw4zCK2rHmNKITq9H35tx0pzpWbGe9elZnz5fXWsu9ax4mzvandi0PXbvqTenW-DnDjDJmuBGM1ifPrjtL6JmUjwDyyOE7w</recordid><startdate>20140701</startdate><enddate>20140701</enddate><creator>TEMPLETON, Arnoud J</creator><creator>ACE, Olga</creator><creator>MCNAMARA, Mairéad G</creator><creator>AL-MUBARAK, Mustafa</creator><creator>VERA-BADILLO, Francisco E</creator><creator>HERMANNS, Thomas</creator><creator>SERUGA, Boštjan</creator><creator>OCANA, Alberto</creator><creator>TANNOCK, Ian F</creator><creator>AMIR, Eitan</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140701</creationdate><title>Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis</title><author>TEMPLETON, Arnoud J ; ACE, Olga ; MCNAMARA, Mairéad G ; AL-MUBARAK, Mustafa ; VERA-BADILLO, Francisco E ; HERMANNS, Thomas ; SERUGA, Boštjan ; OCANA, Alberto ; TANNOCK, Ian F ; AMIR, Eitan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c556t-b2f87612ba5d8cef018473f01866e52dfb8be54ab981fdad3d63503e0644cc813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Biological and medical sciences</topic><topic>Humans</topic><topic>Lymphocyte Count</topic><topic>Medical sciences</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Neoplasms - blood</topic><topic>Neoplasms - mortality</topic><topic>Platelet Count</topic><topic>Prognosis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>TEMPLETON, Arnoud J</creatorcontrib><creatorcontrib>ACE, Olga</creatorcontrib><creatorcontrib>MCNAMARA, Mairéad G</creatorcontrib><creatorcontrib>AL-MUBARAK, Mustafa</creatorcontrib><creatorcontrib>VERA-BADILLO, Francisco E</creatorcontrib><creatorcontrib>HERMANNS, Thomas</creatorcontrib><creatorcontrib>SERUGA, Boštjan</creatorcontrib><creatorcontrib>OCANA, Alberto</creatorcontrib><creatorcontrib>TANNOCK, Ian F</creatorcontrib><creatorcontrib>AMIR, Eitan</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer epidemiology, biomarkers & prevention</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>TEMPLETON, Arnoud J</au><au>ACE, Olga</au><au>MCNAMARA, Mairéad G</au><au>AL-MUBARAK, Mustafa</au><au>VERA-BADILLO, Francisco E</au><au>HERMANNS, Thomas</au><au>SERUGA, Boštjan</au><au>OCANA, Alberto</au><au>TANNOCK, Ian F</au><au>AMIR, Eitan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis</atitle><jtitle>Cancer epidemiology, biomarkers & prevention</jtitle><addtitle>Cancer Epidemiol Biomarkers Prev</addtitle><date>2014-07-01</date><risdate>2014</risdate><volume>23</volume><issue>7</issue><spage>1204</spage><epage>1212</epage><pages>1204-1212</pages><issn>1055-9965</issn><eissn>1538-7755</eissn><coden>CEBPE4</coden><abstract>Inflammation influences cancer development and progression. An elevated platelet to lymphocyte ratio (PLR), a marker of inflammation, has been linked to poor prognosis in several malignancies. Here, we quantify the prognostic impact of this biomarker.
A systematic review of databases was conducted to identify publications exploring the association of blood PLR and overall survival (OS) in solid tumors. Data were pooled in a meta-analysis. Pooled HRs for OS by disease group and by PLR cutoff groups were computed and weighted using generic inverse-variance and random-effect modeling.
Twenty studies comprising 12,754 patients were assessed. Cutoffs for PLR defining risk groups ranged from 150 to 300 and were dichotomous (12 studies; group 1) or split into three groups (<150/150-300/>300, 8 studies; group 2). Higher PLR was associated with significantly worse OS in group 1 [HR = 1.87; 95% confidence interval (CI, 1.49-2.34); P < 0.001] and with a nonsignificant association in group 2 (HR per higher category = 1.21; 95%CI, 0.97-1.50; P = 0.10). The size of effect of PLR on OS was greater for metastatic disease (HR[group 1] = 2.0; 95% CI, 1.6-2.7; HR[group 2] = 1.6; 95% CI, 1.1-2.4) than for early-stage disease (HR[group 1] = 1.5; 95% CI, 1.0-2.2; HR[group 2] = 1.0; 95% CI, 0.8-1.3). A significant association was observed for colorectal, hepatocellular, gastroesophageal, ovarian, and pancreatic carcinoma in group 1 and for colorectal cancers in group 2.
A high PLR is associated with worse OS in various solid tumors. Further research of its regulation and relevance in daily practice is warranted.
PLR is a readily available and inexpensive biomarker with independent prognostic value in solid tumors.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>24793958</pmid><doi>10.1158/1055-9965.epi-14-0146</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1055-9965 |
ispartof | Cancer epidemiology, biomarkers & prevention, 2014-07, Vol.23 (7), p.1204-1212 |
issn | 1055-9965 1538-7755 |
language | eng |
recordid | cdi_proquest_miscellaneous_1543279151 |
source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals |
subjects | Biological and medical sciences Humans Lymphocyte Count Medical sciences Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Neoplasms - blood Neoplasms - mortality Platelet Count Prognosis Tumors |
title | Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T00%3A27%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Role%20of%20Platelet%20to%20Lymphocyte%20Ratio%20in%20Solid%20Tumors:%20A%20Systematic%20Review%20and%20Meta-Analysis&rft.jtitle=Cancer%20epidemiology,%20biomarkers%20&%20prevention&rft.au=TEMPLETON,%20Arnoud%20J&rft.date=2014-07-01&rft.volume=23&rft.issue=7&rft.spage=1204&rft.epage=1212&rft.pages=1204-1212&rft.issn=1055-9965&rft.eissn=1538-7755&rft.coden=CEBPE4&rft_id=info:doi/10.1158/1055-9965.epi-14-0146&rft_dat=%3Cproquest_cross%3E1543279151%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1543279151&rft_id=info:pmid/24793958&rfr_iscdi=true |